Congqin Chen

Fujian Branch Of National Clinical Research Center For Cardiovascular Diseases
Xiamen, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis.

Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis.

Journal: BMC cardiovascular disorders

Published: December 18, 2025

Risk of thromboembolic events in patients co-treated with factor Xa-inhibiting direct oral anticoagulants and anti-seizure medications: insights from pharmacovigilance data.

Risk of thromboembolic events in patients co-treated with factor Xa-inhibiting direct oral anticoagulants and anti-seizure medications: insights from pharmacovigilance data.

Journal: Expert opinion on drug safety

Published: April 30, 2025

Association of Vancomycin Plus Piperacillin-Tazobactam With Acute Kidney Injury: Differentiating Pseudo-Injury From True Nephrotoxicity.

Association of Vancomycin Plus Piperacillin-Tazobactam With Acute Kidney Injury: Differentiating Pseudo-Injury From True Nephrotoxicity.

Journal: Clinical and translational science

Published: January 11, 2025

Suicidal thoughts and behaviors associated with fluoroquinolone antibiotics: a real-world pharmacovigilance analysis.

Suicidal thoughts and behaviors associated with fluoroquinolone antibiotics: a real-world pharmacovigilance analysis.

Journal: Frontiers in pharmacology

Published: January 06, 2025

Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.

Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.

Journal: Frontiers in immunology

Published: December 05, 2023

Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.

Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.

Journal: European psychiatry : the journal of the Association of European Psychiatrists

Published: November 30, 2023

Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study.

Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study.

Journal: International immunopharmacology

Published: November 27, 2023

Updated insights on dementia-related risk of sacubitril/valsartan: A real-world pharmacovigilance analysis.

Updated insights on dementia-related risk of sacubitril/valsartan: A real-world pharmacovigilance analysis.

Journal: CNS neuroscience & therapeutics

Published: November 25, 2022

Real-world evidence of autoimmune hepatitis following COVID-19 vaccination: A population-based pharmacovigilance analysis.

Real-world evidence of autoimmune hepatitis following COVID-19 vaccination: A population-based pharmacovigilance analysis.

Journal: Frontiers in pharmacology

Published: November 17, 2022

Hearing disorder following COVID-19 vaccination: A pharmacovigilance analysis using the Vaccine Adverse Event Reporting System.

Hearing disorder following COVID-19 vaccination: A pharmacovigilance analysis using the Vaccine Adverse Event Reporting System.

Journal: Journal of clinical pharmacy and therapeutics

Published: June 08, 2022

Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.

Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.

Journal: Frontiers in immunology

Published: May 07, 2022

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System.

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System.

Journal: Cardiovascular therapeutics

Published: November 11, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026